Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 - World's Premier Cancer Research Forum
Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements
Rakovina Therapeutics Reports Strong Industry Validation and Emerging Collaborations Following 9th Annual DDR Inhibitors Summit
Rakovina Therapeutics Announces Corporate Update Including up to $1.5 Million in New Financing, Leadership Appointments and Debt Restructuring
Rakovina Therapeutics and Variational AI Expand Collaboration to Advance Next-Generation ATR Inhibitors
Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California
Rakovina Therapeutics Announces Three-Month Q2 ended June 30, 2025 Financial Results and Provides Corporate Update
Rakovina Therapeutics CSO Dr. Mads Daugaard Invited to Present at the 13th Tuscany Retreat on Cancer Research and Apoptosis
Rakovina Therapeutics and NanoPalm Ltd. Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies
RETRANSMISSION - Drilling at Swanson Gold Deposit Confirms Large-Scale Gold Discovery with 1.18 g/t Au over 255.04 metres and 1.65 g/t Au over 136.01 metres
REPEAT - Drilling at Swanson Gold Deposit Confirms Large-Scale Gold Discovery with 1.18 g/t Au over 255.04 metres and 1.65 g/t Au over 136.01 metres
